Every medication, regardless of its intended use, comes with some risks. Unfortunately, they aren't always apparent right away. In some cases, doctors only learn about the risks of some medications ...

this drug that addresses IL-33 may be a therapeutic option in the future, and that is exciting. What are the potential implications of these findings for tailoring COPD treatment strategies in former ...

The surprise finding hints that anti–acid reflux therapy may provide benefit in COPD, possibly by reducing micro-aspirations, ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The Centers for Disease Control and Prevention (CDC) issued a public health warning about prescription medications sold ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

And while there are many medications out there to help people cope with pain, they can often cause their own headaches, to say the very least. Now a pharmaceutical company is potentially on the ...

With a nebulizer, you breathe in the medication via a mask that fits over your mouth and nose. These devices are essential for treating lung-specific diseases like chronic obstructive pulmonary ...

The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD ...

Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years ... potential benefits and efficacy of our drug Ohtuvayre and future poster presentations ...

Sanofi and Regeneron have announced that dupilumab has received FDA approval as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD ...

Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications.

The every-other-week injectable drug is now the first biologic therapy approved by the FDA for treating COPD. In COPD, damage to the lungs leads to inflamed airways that cause breathing difficulty ...